Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated
more hematologic malignancies in patients treated with lenalidomide as maintenance (…

Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

Importance A common justification for high cancer drug prices is the sizable research and
development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of …

Cancer is expected to continue as a major health and economic problem worldwide. Several
factors are contributing to the increasing economic burden imposed by cancer, with the cost …

Importance Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in
patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an …

… Mailankody S, Prasad V. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and
Costs. JAMA Oncol. … Sham Mailankody, MB BS 1 ; Vinay Prasad, MD, MPH 1 …

Using population-based data from Sweden, we identified all multiple myeloma (MM)
patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) …

Outcomes for patients with multiple myeloma (MM) have improved substantially in the past
decade, with improvements in both progression-free survival and overall survival. Many …

Background B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell
therapies have generated responses in patients with advanced myeloma, but relapses …

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate
graft-versus-host disease and minimize CAR T rejection. We evaluated escalating doses …